Maxim Group reduced its price target on Lucid Diagnostics Inc. (NASDAQ:LUCD) from $3 to $2, while maintaining a Buy rating, following the company's weaker-than-expected first-quarter 2026 revenue report of $1.3 million. Despite the revenue miss and a GAAP net loss of $23.6 million, the company is actively pursuing commercialization strategies in anticipation of Medicare reimbursement approval and reported $27.9 million in cash and equivalents. The firm specializes in early detection of esophageal precancer, but the article suggests that AI stocks might offer greater returns.

LENSAR Inc (Nasdaq: LNSR) reported a 9% year-over-year increase in recurring revenue for Q1 2026, reaching $12.6 million, which accounted for approximately 94% of total sales. This shift towards a more repeatable revenue base is a key focus for investors, with MarketBeat listing a consensus price target of $10.00 for the stock. The company specializes in laser-based ophthalmic surgery systems, and its quarterly revenue mix is closely watched as an indicator of its commercial profile and execution in the cataract-surgery platform business.

The Paychex Small Business Jobs Index improved for the third consecutive month in May 2026, reaching its highest level in the current year. This indicates increased job growth among U.S. small businesses, with 14 of the top 20 largest states and 15 of the top 20 largest metros reporting an increase. Additionally, weekly earnings growth continued to rise, and weekly hours worked showed positive growth for the third consecutive month.

Bronstein, Gewirtz & Grossman, LLC has launched an investigation into potential corporate wrongdoing by Stride, Inc. (LRN) and its officers. The firm is encouraging stockholders who purchased Stride securities before October 22, 2024, and still hold them, to contact them for more information and to assist in the investigation. The firm operates on a contingency fee basis for class action lawsuits.

IGC Pharma announced the addition of Mount Sinai as a clinical site for its Phase 2 CALMA trial evaluating IGC-AD1 for agitation in Alzheimer's disease. With approximately 80% of targeted participants having completed the trial, the company is moving toward database lock and topline analysis. This expansion aims to enhance patient access, data integrity, and disciplined execution as the trial nears completion.

IGC Pharma has added the Icahn School of Medicine at Mount Sinai as a new clinical site for its Phase 2 CALMA trial of IGC-AD1, which targets agitation in Alzheimer's disease. With approximately 80% of targeted participants having completed the trial, the study is advancing towards database lock and topline analysis. This addition aims to support final-stage execution, patient access, and data integrity as the trial progresses.

Paychex's Small Business Jobs Index reached 99.34 in May, marking its highest level in 2026 and the third consecutive monthly increase. Weekly earnings growth hit 2.98%, the highest since January 2024, while weekly hours worked increased for the third straight month. This positive trend indicates continued strength in the small business labor market across the U.S.

GlobalFoundries (GFS) has completed its acquisition of Synopsys' ARC Processor IP Solutions business, integrating it into MIPS within GF’s Physical AI portfolio. This move consolidates RISC-V and ARC processor IP, along with ASIP tools and custom silicon, to offer a comprehensive software-to-silicon solution for Physical AI applications in automotive, industrial, and edge markets. The combined platform boasts over 150 patents and 300 IP customers, strengthening GF's position as a holistic technology partner.

The acute pain market is projected to grow significantly from USD 4.5 billion in 2025 to USD 15.5 billion by 2036, driven by an increasing number of surgical procedures, rising trauma cases, and advancements in non-opioid pain management. Key companies like Vertex Pharmaceuticals, Heron Therapeutics, and Neumentum are developing new therapies such as JOURNAVX, ZYNRELEF, and NTM-001. Despite market barriers like concerns over opioid abuse and stringent regulations, the pipeline of emerging treatments is expected to revolutionize treatment dynamics.

Helport AI (NASDAQ: HPAI) has announced commercial validation of its AI Labor model in global consumer finance, with its AI collections achieving 60% higher recovered amounts compared to human teams. The company has secured strategic partnerships across Southeast Asia and Latin America for both its AI loan conversion and AI collections products. This validation positions Helport AI as an infrastructure provider delivering autonomous, expert-level AI systems that directly execute operational business functions for clients, moving beyond traditional software-as-a-service.